The acceleration of biopharmaceutical process development is difficult when traditional experience-based sequential approaches are used. As a result, fully optimized and well understood cell culture processes prior to scale-up are rare. Here we show that an accurate, scalable and simple model able to predict cell growth, cell metabolism, titer and some product quality attributes will significantly accelerate process development, improve process development outcomes and reduce development and production costs. Please click Additional Files below to see the full abstract
One of the key goals in process development for monoclonal antibodies is to improve productivity and...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...
Recently, the pharmaceutical industry is increasingly focusing on early drug development which comes...
The continuous production of biopharmaceuticals combines several advantages: the use of smaller equi...
Biopharmaceutical industry is facing numerous challenges. Increased cost pressure, changing markets,...
The maturation of biopharmaceutical process understanding and technical advances have paved the way ...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
The design of processes to manufacture Cell Based Therapies (CBTs) is particularly challenging due t...
Process development towards the production of difficult-to express proteins in perfusion cultivation...
Continuous biomanufacturing provides many important strategic advantages for the production of prote...
Continuous biomanufacturing provides many important strategic advantages for the production of prote...
Continuous process improvement is required during a biologics process life cycle to increase process...
Batch-to-batch variation causes significant challenges in the production of cell and gene therapies ...
Demand for high-value biologics, a rapidly growing pipeline, and pressure from competition, time-to-...
One of the key goals in process development for monoclonal antibodies is to improve productivity and...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...
Recently, the pharmaceutical industry is increasingly focusing on early drug development which comes...
The continuous production of biopharmaceuticals combines several advantages: the use of smaller equi...
Biopharmaceutical industry is facing numerous challenges. Increased cost pressure, changing markets,...
The maturation of biopharmaceutical process understanding and technical advances have paved the way ...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
The design of processes to manufacture Cell Based Therapies (CBTs) is particularly challenging due t...
Process development towards the production of difficult-to express proteins in perfusion cultivation...
Continuous biomanufacturing provides many important strategic advantages for the production of prote...
Continuous biomanufacturing provides many important strategic advantages for the production of prote...
Continuous process improvement is required during a biologics process life cycle to increase process...
Batch-to-batch variation causes significant challenges in the production of cell and gene therapies ...
Demand for high-value biologics, a rapidly growing pipeline, and pressure from competition, time-to-...
One of the key goals in process development for monoclonal antibodies is to improve productivity and...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...
The biopharmaceutical industry strives to develop and operate efficient, robust, reproducible commer...